Skip to main content
Fig. 1 | BMC Medical Research Methodology

Fig. 1

From: Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva

Fig. 1

An overview of the palovarotene clinical development program for FOP. Across the clinical development program, 164 individuals with FOP had received at least one dose of palovarotene. aIncludes 5 new individuals who had not participated in any previous study. bIn PVO-1A-202 Part D annual assessments were obtained following the last dose of palovarotene in participants who were skeletally immature at the time of treatment discontinuation. FOP: fibrodysplasia ossificans progressiva; NHS: natural history study; OLE: open-label extension; PVO: palovarotene; RCT: randomized controlled trial

Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us